Vinayak Prasad, MD, MPH
Professor
Epidemiology & Biostatistics
School of Medicine
Vinay Prasad MD MPH is Professor of Epidemiology and Biostatistics and Medicine, and a practicing Hematologist Oncologist at San Francisco General Hospital. Dr. Prasad cares for patients with a wide range of medical concerns, including classic hematology, malignant hematology, and solid tumors. He conducts research at the intersection of health policy, evidence based medicine and oncology.
Show full bio (450 words) Hide full bio
Dr. Prasad trained at the University of Chicago, Pritzker School of Medicine, where he was recipient of the Chairman's Award in Internal Medicine, given to the graduate with highest marks in Internal Medicine and its subspecialties. He finished residency in Internal Medicine at Northwestern University, where he won the Gerald Grumet Award for best resident teacher. He completed fellowship at the National Cancer Institute and National Institutes of Health in Hematology and Medical Oncology, where he was Chief Fellow, and a Cancer Prevention Fellow.
Dr. Prasad completed his Masters in Public Health from Johns Hopkins University. For 5 years, Dr. Prasad was Assistant and then Associate Professor at the Oregon Health and Science University, where he won 4 teaching awards in consecutive years (2017-20), including the J David Bristow Award, given by the graduating medical school class to "a faculty member who exemplifies the ideals of the true physician as he or she conducts clinical practice with patients and colleagues," and the Craig Okada award for best teacher in the hematology oncology fellowship program. Dr Prasad moved to UCSF in 2020. In 2022, he won the Excellence in Teaching Award at UCSF, and in 2023, he received the Distinguished Contribution to Teaching Award also at UCSF.
Dr. Prasad studies medical evidence, clinical decision making, health policy, and cancer drug pricing. With Adam Cifu, he coined the term Medical Reversal-- a phenomenon where medical practice flip flops, and published several papers defining its scope and impact. His work on cancer drug policy has defined the appropriate role of surrogate endpoints, and probed issues of cost and value.
He is the author of over 400 peer reviewed papers, including articles in the New England Journal of Medicine, JAMA, BMJ, Nature, the Annals of Internal Medicine and JAMA Internal Medicine. He has also written 2 peer reviewed books, published by Johns Hopkins University Press: Ending Medical Reversal and Malignant. He hosts the podcast Plenary Session, which is the #1 oncology podcast globally by downloads, and the VPZD show, a general interest science show. He is active on Youtube and Substack. On Youtube, the channel Vinay Prasad MD MPH has over 100,000 subscribers. On Substack, Dr Prasad writes Vinay Prasad's Observations and Thoughts, and co-writers Sensible Medicine.
Dr Prasad is the author of over 100 op-eds in media outlets including the New York Times, the Washington Post, STAT, US News and World Report, and many other outlets. He has been the guest on numerous podcasts including Honestly, Breaking Points and EconTalk. He runs the research lab www.vkprasadlab.com, and has supervised over 100 trainees on research papers.
You can learn more about his work on www.vinayakkprasad.com and https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Education & Training
Show all (1) Hide
- MD Medicine University of Chicago
Interests
Show all (5) Hide
- Bias
- Evidence based medicine
- Meta-research
- Health policy
- Randomized trials
Websites
Show all (3) Hide
- Personal Website (vinayakkprasad.com)
- Podcast Website (plenarysessionpodcast.com)
- Laboratory Website (vkprasadlab.com)
Videos
Show all (3) Hide
- Lecture 1 - Lay of the Land (youtube.com)
- Lecture 2 - Surrogate Endpoints (youtube.com)
- Lecture 3 - FDA Approval of Surrogates (youtube.com)
Grants and Projects
Show all (1) Hide
- Low and No Value Care, Arnold Ventures
Publications (511)
Top publication keywords:
OncologistsRandomized Controlled Trials as TopicPeriodicals as TopicMedical OncologyAntineoplastic AgentsClinical Trials as TopicDrug IndustryConflict of InterestUnited States Food and Drug AdministrationDrug ApprovalHumansDrug CostsResearch DesignEvidence-Based MedicineNeoplasms
-
A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals.
eLife 2019 Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu AS, Prasad V -
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
JAMA internal medicine 2019 Chen EY, Joshi SK, Tran A, Prasad V -
Low-value approvals and high prices might incentivize ineffective drug development.
Nature reviews. Clinical oncology 2018 Prasad V, McCabe C, Mailankody S -
Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes.
CMAJ open 2018 Hayes MJ, Kaestner V, Mailankody S, Prasad V -
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
JAMA internal medicine 2017 Prasad V, Mailankody S -
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
BMC medicine 2017 Kemp R, Prasad V -
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
JAMA oncology 2015 Mailankody S, Prasad V
Show all (504 more) Hide
-
COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementation.
Monash bioethics review 2024 Prasad V, Haslam A -
Justification for unequal allocation ratios in clinical trials: A scoping review.
Contemporary clinical trials 2024 Nay J, Haslam A, Prasad V -
Estimation of eligibility for and response to CAR-T therapy in the United States.
Blood advances 2024 Haslam A, Hoeg TB, Prasad V -
Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops.
European journal of clinical investigation 2024 Miller SL, Haslam A, Prasad V -
Equal censoring but still informative: When the reasons for censoring differ between treatment arms.
European journal of cancer (Oxford, England : 1990) 2024 Olivier T, Prasad V -
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds.
Epidemiology and infection 2024 Høeg TB, Haslam A, Prasad V -
Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials.
European journal of cancer (Oxford, England : 1990) 2024 Wu AQ, Benjamin DJ, Prasad V, Olivier T -
T-Cell Lymphoma From CAR T-Cell Therapy-A New Safety Notice.
JAMA 2024 Prasad V -
Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer.
The oncologist 2024 Benjamin DJ, Prasad V -
Analysis of tweets discussing the risk of Mpox among children and young people in school (May-October 2022): a retrospective observational study.
BMJ paediatrics open 2024 Knudsen B, Høeg TB, Prasad V -
COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities.
Journal of medical ethics 2024 Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary MA, Baral S, Høeg TB -
University-age vaccine mandates: reply to Lam and Nichols.
Journal of medical ethics 2024 Høeg TB, Krug A, Baral S, Jamrozik E, Keshavjee S, Lemmens T, Prasad V, Makary MA, Bardosh K -
Sotorasib in KRASG12C mutated lung cancer.
Lancet (London, England) 2024 Olivier T, Prasad V -
Concerns That May Limit the Utility of Zuranolone.
JAMA 2024 Prasad V, Allely D -
Discrepancies in Estimating Excess Death by Political Party Affiliation During the COVID-19 Pandemic.
JAMA internal medicine 2024 Dasaro C, Haslam A, Prasad V -
The Ethical Obligation for Research During Public Health Emergencies: Insights From the COVID-19 Pandemic.
Medicine, health care, and philosophy 2023 Barosa M, Jamrozik E, Prasad V -
Assessing patient burden and benefit: A decade of cabozantinib clinical trials.
International journal of cancer 2023 Hughes GK, Sajjadi NB, Gardner B, Ramoin JK, Tuia J, Haslam A, Prasad V, Vassar M -
Reliance on the highest-quality studies of Long Covid is appropriate and not evidence of bias.
BMJ evidence-based medicine 2023 Høeg TB, Ladhani S, Prasad V -
Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy.
Journal of cancer policy 2023 Ranganathan S, Haslam A, Tuia J, Prasad V -
Cancer Drug Price and Novelty in Mechanism of Action.
JAMA network open 2023 Miljkovic MD, Tuia J, Olivier T, Haslam A, Prasad V -
Rapid antigen testing for COVID-19: Decreasing diagnostic reliability, potential detrimental effects and a lack of evidence to support continued public funding of community-based testing.
Public health in practice (Oxford, England) 2023 Høeg TB, Prasad V -
Starting and stopping cancer drugs: The need for randomized trials.
Journal of cancer policy 2023 Benjamin DJ, Prasad V -
Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout.
The American journal of medicine 2023 Haslam A, Tuia J, Miller SL, Prasad V -
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.
Nature reviews. Clinical oncology 2023 Walia A, Tuia J, Prasad V -
Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.
JAMA network open 2023 Olivier T, Haslam A, Tuia J, Prasad V -
An Analysis of Studies Pertaining to Masks in Morbidity and Mortality Weekly Report: Characteristics and Quality of Studies through 2023.
The American journal of medicine 2023 Høeg TB, Haslam A, Prasad V -
How methodological pitfalls have created widespread misunderstanding about long COVID.
BMJ evidence-based medicine 2023 Høeg TB, Ladhani S, Prasad V -
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
The New England journal of medicine 2023 Allely D, Prasad V -
Flu advice in the U.S. news media changed during the COVID-19 pandemic but not the evidence.
European journal of epidemiology 2023 Brown E, Haslam A, Prasad V -
Does equipoise exist for masking children for COVID-19?
Public health in practice (Oxford, England) 2023 Høeg TB, González-Dambrauskas S, Prasad V -
Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer.
BMC medicine 2023 Olivier T, Haslam A, Prasad V -
Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs.
JAMA oncology 2023 Lam M, Olivier T, Haslam A, Tuia J, Prasad V -
Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast.
JAMA internal medicine 2023 Mohyuddin GR, Prasad V -
Extended anticoagulation for VTE: what evidence justifies it?
Frontiers in pharmacology 2023 Walia A, Prasad V -
Financial conflicts of interest of physicians followed by oncology journals on Twitter.
Journal of cancer research and clinical oncology 2023 Betts C, Kakkilaya A, Vasireddy S, Arora N, Prasad V, Powell K -
Evidence Base for Health Care Strategies to Protect Vulnerable Patients During the COVID-19 Pandemic.
JAMA oncology 2023 Haslam A, Prasad V -
Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19.
The New England journal of medicine 2023 Høeg TB, Duriseti R, Prasad V -
Multiple myeloma: challenges with deciding the optimal sequencing strategy.
Frontiers in pharmacology 2023 Walia A, Haslam A, Tuia J, Prasad V -
Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use.
Trials 2023 Prasad V, Kim MS, Haslam A -
Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022.
Journal of cancer policy 2023 Olivier T, Smith CEP, Haslam A, Addeo A, Prasad V -
Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals.
JAMA network open 2023 Haslam A, Tuia J, Prasad V -
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020.
BMC cancer 2023 Olivier T, Haslam A, Prasad V -
Profile of the Oncology Physician Workforce and the Characteristics of Attrition.
JCO oncology practice 2023 Tuia J, Haslam A, Prasad V -
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC.
Journal of cancer research and clinical oncology 2023 Walia A, Prasad V -
PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings.
Journal of cancer research and clinical oncology 2023 Olivier T, Prasad V -
Cross-sectional analysis of open payments for physicians at designated hemophilia centers in the US (2018-2020).
Thrombosis research 2023 Haslam A, Prasad V -
Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis.
JAMA internal medicine 2023 Banerjee T, Kim MS, Haslam A, Prasad V -
The United States' decision to mask children as young as two for COVID-19 has been extended into 2023 and beyond: The implications of this policy.
Paediatric respiratory reviews 2023 Høeg TB, González-Dambrauskas S, Prasad V -
Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials?
Journal of cancer policy 2023 Olivier T, Haslam A, Prasad V -
The definition of long COVID used in interventional studies.
European journal of clinical investigation 2023 Haslam A, Olivier T, Prasad V -
Unknown Causes of Death in Cancer Patients.
American journal of clinical oncology 2023 Chinniah S, Chiam M, Mani K, Liang M, Trifiletti DM, Spratt DE, Prasad VK, Wang M, Tchelebi LT, Zaorsky NG -
Chaotic advection in a recirculating flow: Effect of a fluid multiple-flexible-solid interaction.
Chaos (Woodbury, N.Y.) 2023 Prasad V, Sharma A, Kulkarni SS -
Omission of Critical Information From Clinical Trial Reports-What to Do About Uninterpretable Results.
JAMA oncology 2023 Olivier T, Haslam A, Prasad V -
The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review.
Journal of cancer research and clinical oncology 2023 Bhatt A, Haslam A, Prasad V -
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm.
Blood cancer journal 2023 Walia A, Prasad V -
An evidence double standard for pharmacological versus non-pharmacological interventions: Lessons from the COVID-19 pandemic.
Contemporary clinical trials communications 2023 Høeg TB, Prasad VK -
CME: Is it Meeting the Mark?
The American journal of medicine 2023 Ranganathan S, Prasad V -
The Reply.
The American journal of medicine 2023 Olivier T, Gill J, Prasad V -
Visualizing the randomized sham-controlled trial in orthopedic research: proposed steps to conducting a total knee arthroplasty randomized controlled trial.
Journal of comparative effectiveness research 2023 Tran AA, Prasad V -
The response rate by tumour type for tissue-agnostic approved drugs.
European journal of cancer (Oxford, England : 1990) 2023 Haslam A, Prasad V -
Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
European urology 2023 Olivier T, Tsantoulis P, Prasad V -
Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
European urology 2023 Varatharajan A, Olivier T, Prasad V -
Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology.
Journal of cancer policy 2023 Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin GR -
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
American journal of hematology 2023 Walia A, Prasad V -
Interpreting the results from the first randomised controlled trial of colonoscopy: does it save lives?
BMJ evidence-based medicine 2023 Powell K, Prasad V -
Front-line chronic lymphocytic leukemia: The role of chemoimmunotherapy.
American journal of hematology 2023 Kim MS, Prasad V -
Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals.
JAMA network open 2023 Buck E, Haslam A, Tuia J, Prasad V -
Comparability of Control and Comparison Groups in Studies Assessing Long COVID.
The American journal of medicine 2023 Haslam A, Prasad V -
Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers.
BMC cancer 2023 Haslam A, Olivier T, Tuia J, Prasad V -
Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?
Journal of cancer policy 2023 Khaki AR, Lythgoe MP, Prasad V -
The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial.
Future oncology (London, England) 2023 Powell K, Marquart J, Olivier T, Prasad V -
COVID-19 vaccine induced myocarditis in young males: A systematic review.
European journal of clinical investigation 2023 Knudsen B, Prasad V -
Financial conflicts of interest of physicians followed by neurosurgical journals on Twitter.
The International journal of health planning and management 2023 Powell K, McCall K, Hooda K, Prasad V, Kakkilaya A -
Paxlovid: A Regulatory Gamble.
The American journal of medicine 2023 Miljkovic MD, Prasad V -
Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
Translational oncology 2022 Olivier T, Haslam A, Prasad V -
A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer.
Trials 2022 Powell K, Olivier T, Prasad V -
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
British journal of haematology 2022 Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR -
Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.
JAMA internal medicine 2022 Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V -
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.
Blood cancer journal 2022 Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR -
Financial conflicts of interest of OncoAlert: An informal oncology professional network.
Journal of cancer policy 2022 Powell K, Kakkilaya A, Haslam A, Prasad V -
Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment.
BMC medicine 2022 Olivier T, Prasad V -
A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target.
European journal of cancer (Oxford, England : 1990) 2022 Haslam A, Olivier T, Tuia J, Prasad V -
Pembrolizumab for all.
Journal of cancer research and clinical oncology 2022 Kim MS, Prasad V -
Brentuximab Vedotin in Advanced Hodgkin's Lymphoma.
The New England journal of medicine 2022 Haslam A, Prasad V -
What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).
BMJ open 2022 Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V -
Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis.
Journal of cancer policy 2022 Prasad V, Olivier T, Chen EY, Haslam A -
FDA validation of surrogate endpoints in oncology: 2005-2022.
Journal of cancer policy 2022 Walia A, Haslam A, Prasad V -
Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint.
European urology 2022 Powell K, Burns MC, Prasad V -
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
European urology 2022 Olivier T, Powell K, Prasad V -
Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care.
American journal of clinical oncology 2022 Tuia JE, Olivier T, Prasad VK -
The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
Translational oncology 2022 Bhatt A, Powell K, Prasad V -
Control participants of randomised trials: an often forgotten, vulnerable population.
The Lancet. Haematology 2022 Mohyuddin GR, Mehra N, Ryll B, Prasad V -
Characteristics of Facebook's third-party medical fact checkers.
Digital health 2022 Haslam A, Prasad V -
Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?
Translational oncology 2022 Olivier T, Prasad V -
Constructive and obsessive criticism in science.
European journal of clinical investigation 2022 Prasad V, Ioannidis JPA -
PI3K inhibitors in haematological malignancies.
The Lancet. Oncology 2022 Benjamin DJ, Prasad V -
Common misconceptions of randomized controlled trials in oncology.
European journal of clinical investigation 2022 Powell K, Prasad V -
Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021.
European journal of cancer (Oxford, England : 1990) 2022 Olivier T, Haslam A, Prasad V -
CostPlus and implications for generic imatinib.
Lancet regional health. Americas 2022 Jenei K, Lythgoe MP, Prasad V -
Eventual success rate and predictors of success for oncology drugs tested in phase I trials.
International journal of cancer 2022 Haslam A, Olivier T, Powell K, Tuia J, Prasad V -
Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines.
Translational oncology 2022 Olivier T, Prasad V -
Contact Tracing Policy for Masked Students May be an Important Confounding Variable.
Pediatrics 2022 Høeg TB, Prasad V, Porter T -
Ivosidenib and Azacitidine in IDH1-Mutated AML.
The New England journal of medicine 2022 Goodman AM, Mohyuddin GR, Prasad V -
Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.
British journal of cancer 2022 Lythgoe MP, Prasad V -
Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials.
Blood advances 2022 Olivier T, Prasad V, Marini BL -
Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?
JCO oncology practice 2022 Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM -
General payments from Biogen to U.S. physicians between 2015 and 2020.
Journal of the American Geriatrics Society 2022 Jenei K, Lythgoe MP, Prasad V -
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.
JAMA network open 2022 Mousavi I, Olivier T, Prasad V -
Corrigendum to 'Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized' AmJMed 2021;135(4):413-415.
The American journal of medicine 2022 Olivier T, Gill J, Prasad V -
Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries.
Revista panamericana de salud publica = Pan American journal of public health 2022 Sandoval GA, Totanes R, David AM, Fu D, Bettcher D, Prasad V, Arnold V -
Multiplicity: When many analytic plans are applied or many redundant studies are run, false-positive results are ensured.
European journal of clinical investigation 2022 Powell K, Prasad V -
FDA precedents in drug approvals: Contradiction in promoting more treatment options.
European journal of cancer (Oxford, England : 1990) 2022 Olivier T, Prasad V -
Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials.
JAMA network open 2022 Ahmed N, Vengalasetti Y, Haslam A, Prasad V -
Accelerated approval requirements for lurbinectedin.
The Lancet. Oncology 2022 Benjamin DJ, Prasad V -
FDA decisions on new oncological drugs.
The Lancet. Oncology 2022 Benjamin DJ, Prasad V, Lythgoe MP -
The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review.
The American journal of medicine 2022 Iness AN, Abaricia JO, Sawadogo W, Iness CM, Duesberg M, Cyrus J, Prasad V -
Chaotic advection in a recirculating flow: Effect of a fluid-flexible-solid interaction.
Chaos (Woodbury, N.Y.) 2022 Prasad V, Kulkarni SS, Sharma A -
Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident.
European journal of emergency medicine : official journal of the European Society for Emergency Medicine 2022 Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V -
Tebentafusp in first-line melanoma trials: An outperforming outlier.
Translational oncology 2022 Olivier T, Prasad V -
High US drug prices have global implications.
BMJ (Clinical research ed.) 2022 Jenei K, Prasad V, Lythgoe MP -
Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Cancer medicine 2022 Benjamin DJ, Haslam A, Gill J, Prasad V -
Characteristics of oncology podcasts: Attitudes, speakers, conflicts.
Journal of cancer policy 2022 Akman EG, Powell K, Haslam A, Prasad V -
Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Olivier T, Prasad V -
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
JAMA network open 2022 Benjamin DJ, Xu A, Lythgoe MP, Prasad V -
Post-protocol therapy and informative censoring in the CANDOR study.
The Lancet. Oncology 2022 Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR -
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply.
JAMA oncology 2022 Jenei K, Meyers DE, Prasad V -
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review.
European journal of cancer (Oxford, England : 1990) 2022 Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR -
Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
International journal of cancer 2022 Kim MS, Xu A, Haslam A, Prasad V -
The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall.
Journal of comparative effectiveness research 2022 Xu A, Prasad V -
The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
Translational oncology 2022 Olivier T, Prasad V -
Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.
European journal of cancer (Oxford, England : 1990) 2022 Maniar A, Haslam A, Prasad V -
Retrospective comparative effectiveness research: Will changing the analytical methods change the results?
International journal of cancer 2022 Zaorsky NG, Wang X, Lehrer EJ, Tchelebi LT, Yeich A, Prasad VK, Chinchilli VM, Wang M -
The accelerated approval pathway in oncology: Balancing the benefits and potential harms.
Journal of cancer policy 2022 Wayant C, Mohyuddin GR, Prasad V -
Regulatory decisions diverge over aducanumab for Alzheimer's disease.
BMJ (Clinical research ed.) 2022 Lythgoe MP, Jenei K, Prasad V -
The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer.
Journal of cancer policy 2022 Lythgoe MP, Prasad V -
An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
BMC cancer 2022 Sharp J, Prasad V -
Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials.
JAMA network open 2022 Olivier T, Haslam A, Prasad V -
Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature.
JAMA internal medicine 2022 Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V -
How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature.
Inquiry : a journal of medical care organization, provision and financing 2022 Haslam A, Powell K, Prasad V -
A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers.
Journal of cancer policy 2021 Prasad V, Haslam A, Tuia J -
Where are randomized trials necessary: Are smoking and parachutes good counterexamples?
European journal of clinical investigation 2021 Powell K, Prasad V -
Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
JAMA network open 2021 Olivier T, Haslam A, Prasad V -
Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing.
JAMA oncology 2021 Fundytus A, Prasad V, Booth CM -
The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?
Nature reviews. Clinical oncology 2021 Lythgoe MP, Prasad V -
Artificial intelligence and magnetic resonance imaging may not make cancer screening better.
Journal of cancer policy 2021 Powell K, Kim MS, Haslam A, Prasad V -
The frequency of assessment of progression in randomized oncology clinical trials.
Cancer reports (Hoboken, N.J.) 2021 Haslam A, Gill J, Prasad V -
Overall survival for oncology drugs approved for genomic indications.
European journal of cancer (Oxford, England : 1990) 2021 Haslam A, Kim MS, Prasad V -
Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?
Translational oncology 2021 Olivier T, Prasad V -
Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
British journal of haematology 2021 Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR -
Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.
JAMA network open 2021 Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V -
Cost-Effectiveness of Population Level and Individual Level Interventions to Combat Non-communicable Disease in Eastern Sub-Saharan Africa and South East Asia: A WHO-CHOICE Analysis.
International journal of health policy and management 2021 Bertram MY, Chisholm D, Watts R, Waqanivalu T, Prasad V, Varghese C -
Implementation of MPOWER Package in the South-East Asia Region: Evidence from the WHO Report on the Global Tobacco Epidemic (2009-2021).
Asian Pacific journal of cancer prevention : APJCP 2021 Kaur J, Rinkoo AV, Gouda HN, Prasad V, Pendse RN -
The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval.
JAMA oncology 2021 Powell K, Lythgoe MP, Prasad V -
The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy.
European journal of cancer (Oxford, England : 1990) 2021 Lythgoe MP, Olivier T, Prasad V -
Tobacco Advertising, Promotion and Sponsorship in India and Indonesia: Present Regime and the Way Forward.
Asian Pacific journal of cancer prevention : APJCP 2021 Chandra S, Rinkoo AV, Kaur J, Prasad V -
Tobacco Control in the South-East Asia Region: Accelerating Impact by Building on the Achievements and Navigating the Challenges.
Asian Pacific journal of cancer prevention : APJCP 2021 Prasad V, Kaur J -
Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
Journal of cancer policy 2021 Jenei K, Raymakers A, Meyers DE, Prasad V -
Recommendation Reversals in Gastroenterology Clinical Practice Guidelines.
Journal of the Canadian Association of Gastroenterology 2021 Gholami R, Khan R, Ramkissoon A, Alabdulqader A, Gimpaya N, Bansal R, Scaffidi MA, Prasad V, Detsky AS, Baker JP, Grover SC -
An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence Based?
The American journal of medicine 2021 Powell K, Haslam A, Prasad V -
Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm.
Translational oncology 2021 Olivier T, Prasad V -
Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized.
The American journal of medicine 2021 Olivier T, Gill J, Prasad V -
Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF.
BMJ evidence-based medicine 2021 Powell K, Prasad V -
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study.
Cancer 2021 Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM -
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years.
JAMA oncology 2021 Jenei K, Meyers DE, Prasad V -
Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination.
Frontiers of medicine 2021 Kulkarni PA, Prasad V -
How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
European journal of cancer (Oxford, England : 1990) 2021 Lythgoe MP, Prasad V -
The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting.
Mayo Clinic proceedings 2021 Gill J, Sarpatwari A, Prasad V -
Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.
JAMA network open 2021 Sharp J, Khaki AR, Prasad V -
An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals.
Digestive diseases and sciences 2021 Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B -
Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.
European journal of cancer (Oxford, England : 1990) 2021 Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V -
Idecabtagene vicleucel: questions regarding the appropriate role and cost.
British journal of haematology 2021 Powell K, Russler-Germain D, Prasad V -
Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge.
European journal of cancer (Oxford, England : 1990) 2021 Kim MS, Prasad V -
The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018.
BMC cancer 2021 Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V -
After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems.
International journal of cancer 2021 Gill J, Prasad V -
Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials.
Journal of clinical epidemiology 2021 Olivier T, Haslam A, Prasad V -
Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review.
JAMA network open 2021 Banerjee R, Prasad V -
New drugs and options can enhance patient outcomes: But can they also erode them?
European journal of cancer (Oxford, England : 1990) 2021 Kim MS, Prasad V -
Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?
European journal of clinical investigation 2021 Prasad V -
The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
Leukemia & lymphoma 2021 Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V -
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100.
BMJ evidence-based medicine 2021 Kim MS, Prasad V -
The regulatory saga of fedratinib.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021 Khal S, Prasad V, Palumbo A -
Assessment of New Molecular Entities Approved for Cancer Treatment in 2020.
JAMA network open 2021 Smith CEP, Prasad V -
Accurate accounting of caplacizumab cost effectiveness.
The Lancet. Haematology 2021 Goshua G, Prasad V, Lee AI, Bendapudi PK -
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
JAMA oncology 2021 Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM -
Multiple myeloma triplet therapies: baseline characteristics and control groups.
Lancet (London, England) 2021 Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V -
Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?
Journal of general internal medicine 2021 Desai A, Prasad V -
Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets.
Journal of cancer policy 2021 Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V, Booth CM -
Old-fashioned Intelligence Will Always Be Needed in Medicine.
European urology focus 2021 Powell K, Prasad V -
Approval and Coverage of Cancer Drugs in England, Canada, and the US.
JAMA internal medicine 2021 Prasad V, Kim MS -
Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence.
JAMA oncology 2021 Gill J, Prasad V -
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review.
The Lancet. Haematology 2021 Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V -
Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review.
JAMA network open 2021 Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V -
Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
European urology 2021 Kwon DH, Booth CM, Prasad V -
Improvement of Pediatric Liver Core Biopsy Adequacy by Reducing Laboratory-Related Tissue Fragmentation and Increasing Portal Tract Yield.
American journal of clinical pathology 2021 Liang J, Abbuhl MF, Wang H, Prasad V, Coogan A -
Case report of a skip segment Hirschsprung's disease: A real phenomenon.
International journal of surgery case reports 2021 El-Gohary Y, Skerritt C, Prasad V, Halaweish I, Wood RJ -
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors.
JTO clinical and research reports 2021 Kareff SA, Samtani S, Burotto M, Prasad V, Kim C -
Drug Approvals in Hepatocellular Carcinoma-Filling the Nonexistent Gap?
JAMA oncology 2021 Desai A, Prasad V -
Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
JAMA internal medicine 2021 DeMartino PC, Miljkovic MD, Prasad V -
Targeted Cancer Therapies.
American family physician 2021 Smith CEP, Prasad V -
Persistent challenges with treating multiple myeloma early.
Blood 2021 Goodman AM, Kim MS, Prasad V -
N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA.
Trends in cancer 2021 Gill J, Prasad V -
Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma.
JCO oncology practice 2021 Chen EY, Cook M, Deig C, Arastu A, Prasad V, Nabavizadeh N, Lopez CD, Kardosh A -
Considering benefit and risk before routinely recommending SpaceOAR.
The Lancet. Oncology 2021 Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF -
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19.
Nature reviews. Clinical oncology 2021 Banerjee R, Prasad V -
Drug repurposing in oncology - Authors' reply.
The Lancet. Oncology 2020 Tran AA, Prasad V -
Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform.
BMJ evidence-based medicine 2020 Torgerson T, Wayant C, Cosgrove L, Akl EA, Checketts J, Dal Re R, Gill J, Grover SC, Khan N, Khan R, Marušic A, McCoy MS, Mitchell A, Prasad V, Vassar M -
Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
European journal of cancer (Oxford, England : 1990) 2020 Rosen K, Prasad V, Chen EY -
Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?
European journal of cancer (Oxford, England : 1990) 2020 Tao DL, Kartika T, Tran A, Prasad V -
Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy.
The Lancet. Oncology 2020 Tran AA, Prasad V -
The response rate of alternative treatments for drugs approved on the basis of response rate.
International journal of cancer 2020 Haslam A, Gill J, Prasad V -
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No.
Annals of oncology : official journal of the European Society for Medical Oncology 2020 Prasad V, Addeo A -
Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
JAMA internal medicine 2020 Hilal T, Gonzalez-Velez M, Prasad V -
Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?"
PharmacoEconomics 2020 Tran A, Prasad V -
Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
Leukemia research 2020 Tran AA, Miljkovic M, Prasad V -
US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
Cancer 2020 Kim MS, Prasad V -
Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?
JAMA network open 2020 Banerjee R, Prasad V -
Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?
PharmacoEconomics 2020 Tran AA, Prasad V -
A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.
Trends in cancer 2020 Gill J, Cetnar JP, Prasad V -
The necessity of continuing to ban tobacco use in public places post-COVID-19.
Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 2020 El-Awa F, Fraser CP, Adib K, Hammerich A, Abdel Latif N, Fayokun R, Prasad V, Fu D, Vestal G, Schotte K, Gouda H, St Claire S -
Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis.
BMJ open 2020 Tran A, Klossner Q, Crain T, Prasad V -
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019.
JAMA internal medicine 2020 Chen EY, Haslam A, Prasad V -
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
Cancer 2020 Nishikawa G, Booth C, Prasad V -
Estimation of US patients with cancer who may respond to cytotoxic chemotherapy.
Future science OA 2020 Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V -
Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists.
JAMA internal medicine 2020 Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V -
Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR).
Mayo Clinic proceedings 2020 Herrera-Perez D, Fox-Lee R, Bien J, Prasad V -
The Reply.
The American journal of medicine 2020 Mandrola J, Cifu A, Prasad V, Foy A -
The evidence landscape in precision medicine.
Science translational medicine 2020 Hey SP, Gerlach CV, Dunlap G, Prasad V, Kesselheim AS -
Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers.
JAMA network open 2020 Parsons S, Maldonado EB, Prasad V -
Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Hazim A, Mills G, Prasad V, Haslam A, Chen EY -
Acute histologic inflammatory activity and postoperative outcomes in pediatric patients with ulcerative colitis.
American journal of surgery 2020 Onwuka E, Huntington J, Onwuka A, Prasad V, Nwomeh B -
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs.
JAMA network open 2020 Haslam A, Gill J, Prasad V -
Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials.
JAMA network open 2020 Haslam A, Herrera-Perez D, Gill J, Prasad V -
News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines.
Mayo Clinic proceedings 2020 Krigel A, Prasad VK, Lebwohl B -
Statistical significance and clinical evidence - Authors' reply.
The Lancet. Oncology 2020 Prasad V, Booth CM -
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
The New England journal of medicine 2020 Prasad V -
Medical Reversals in Family Practice: A Review.
Current therapeutic research, clinical and experimental 2020 Haslam A, Livingston C, Prasad V -
An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Haslam A, Gill J, Prasad V -
Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington.
JAMA internal medicine 2020 Ahn R, Herrera-Perez D, Prasad V -
Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions.
Mayo Clinic proceedings 2020 Haslam A, Gill J, Prasad V -
The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.
JAMA internal medicine 2020 Kim MS, Prasad V -
Comparison of three multi-cryoprotectant loading protocols for vitrification of porcine articular cartilage.
Cryobiology 2020 Wu K, Shardt N, Laouar L, Chen Z, Prasad V, Elliott JAW, Jomha NM -
Our best weapons against cancer are not magic bullets.
Nature 2020 Prasad V -
Concerning survival signal for eltrombopag in MDS/AML.
Leukemia & lymphoma 2019 Tao D, Prasad V -
Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Khaki AR, Gadi VK, Prasad V -
Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.
Current oncology (Toronto, Ont.) 2019 Gay ND, Tao D, Prasad V -
Multiplicity in oncology randomised controlled trials: a threat to medical evidence?
The Lancet. Oncology 2019 Prasad V, Booth CM -
Examining the Use of Real-World Evidence in the Regulatory Process.
Clinical pharmacology and therapeutics 2019 Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, Yu KH -
Medical reversals in low- and middle-income countries.
The International journal of health planning and management 2019 Haslam A, Prasad V, Livingston C -
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
JAMA network open 2019 de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V -
A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment.
Research and practice in thrombosis and haemostasis 2019 Gill J, Prasad V -
Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.
Cancer medicine 2019 Aspinall SL, Zhao X, Geraci MC, Good CB, Cunningham FE, Heron BB, Becker D, Lee S, Prasad V, Targeted Therapies in Veterans with RCC Study Group -
The Reply.
The American journal of medicine 2019 Mandrola J, Cifu A, Prasad V, Foy A -
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.
Journal of cancer research and clinical oncology 2019 Luo J, Nishikawa G, Prasad V -
A reality check of the accelerated approval of immune-checkpoint inhibitors.
Nature reviews. Clinical oncology 2019 Gill J, Prasad V -
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
JAMA internal medicine 2019 Chen EY, Raghunathan V, Prasad V -
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
JAMA oncology 2019 Hilal T, Sonbol MB, Prasad V -
Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?
Mayo Clinic proceedings 2019 Chapa J, Haslam A, Prasad V -
Real-world Evidence-What Does It Really Mean?
JAMA oncology 2019 Nabhan C, Klink A, Prasad V -
Registration studies - when should patients be deemed ineligible for aggressive therapy?
Nature reviews. Clinical oncology 2019 Cook RJ, Gill J, Prasad V -
Confirmatory Trials for Drugs Approved on a Single Trial.
Circulation. Cardiovascular quality and outcomes 2019 Haslam A, Prasad V -
Should Evidence Come with an Expiration Date?
Journal of general internal medicine 2019 Greene P, Prasad V, Cifu A -
Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.
JAMA network open 2019 Kim MS, Prasad V -
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
JAMA network open 2019 Haslam A, Prasad V -
Reply to C.J. Sweeney et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Parikh RB, Prasad V -
Case Reports in the Age of Twitter.
The American journal of medicine 2019 Cifu AS, Vandross AL, Prasad V -
Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither?
The American journal of medicine 2019 Gill J, Prasad V -
Untitled Publication
Recenti progressi in medicina 2019 Mandrola J, Cifu A, Prasad V, Foy A -
Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019 Gill J, Prasad V -
The Case for Being a Medical Conservative.
The American journal of medicine 2019 Mandrola J, Cifu A, Prasad V, Foy A -
Cancer screening: A modest proposal for prevention.
Cleveland Clinic journal of medicine 2019 Kim MS, Nishikawa G, Prasad V -
Improving the design of pivotal clinical trials.
Clinical advances in hematology & oncology : H&O 2019 Prasad VK -
Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs.
The American journal of medicine 2019 Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V -
Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Parikh RB, Prasad V -
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.
European journal of cancer (Oxford, England : 1990) 2018 Haslam A, Hey SP, Gill J, Prasad V -
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply.
JAMA oncology 2018 Hernandez I, Prasad V, Gellad WF -
Addendum: Low-value approvals and high prices might incentivize ineffective drug development.
Nature reviews. Clinical oncology 2018 Prasad V, McCabe C, Mailankody S -
Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
Cardiovascular drugs and therapy 2018 Ahn R, Prasad V -
Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
Cardiovascular drugs and therapy 2018 Ahn R, Prasad V -
Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission.
Nature reviews. Clinical oncology 2018 Hilal T, Prasad V -
Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply.
JAMA oncology 2018 Marquart J, Chen EY, Prasad V -
Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
European journal of cancer (Oxford, England : 1990) 2018 Shanbhag S, Prasad V -
Inconsistent Reporting of Potential Conflicts of Interest.
JAMA internal medicine 2018 Prasad V -
Inconsistent Reporting of Potential Conflicts of Interest.
JAMA oncology 2018 Prasad V -
Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies.
Journal of oncology practice 2018 Ahmed AA, Yoo SK, Mehta S, Holliday EB, Deville C, Vapiwala N, Wilson LD, Jagsi R, Prasad V, Thomas CR -
Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were.
BMJ (Clinical research ed.) 2018 Nishikawa G, Prasad V -
The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
The American journal of medicine 2018 Tao D, Schott S, Prasad V -
Choice of control group in randomised trials of cancer medicine: are we testing trivialities?
The Lancet. Oncology 2018 Tao D, Prasad V -
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply.
JAMA oncology 2018 Prasad V, Kaestner V, Mailankody S -
Improving observational studies in the era of big data.
Lancet (London, England) 2018 Gill J, Prasad V -
Inconsistent Reporting of Potential Conflicts of Interest.
JAMA pediatrics 2018 Prasad V -
A pooled analysis of published, basket trials in cancer medicine.
European journal of cancer (Oxford, England : 1990) 2018 Hazim A, Prasad V -
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
JAMA oncology 2018 Marquart J, Chen EY, Prasad V -
The Necessity of Sham Controls.
The American journal of medicine 2018 Prasad V, Cifu AS -
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature.
European journal of cancer (Oxford, England : 1990) 2018 Nishikawa G, Luo J, Prasad V -
Inconsistent Reporting of Potential Conflicts of Interest.
JAMA 2018 Prasad V -
Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.
JAMA pediatrics 2018 Prasad V -
Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That?
Circulation. Cardiovascular quality and outcomes 2018 Haslam A, Prasad V -
PFO closure for secondary stroke prevention: is the discussion closed?
Journal of thrombosis and thrombolysis 2018 Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG -
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.
JAMA oncology 2018 Hernandez I, Prasad V, Gellad WF -
Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
JAMA 2018 Gill J, Obley AJ, Prasad V -
The need to assess financial adverse events.
The Lancet. Haematology 2018 Nastoupil LJ, Prasad V, Flowers CR -
If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis.
Journal of general internal medicine 2018 Deloughery EP, Prasad V -
Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration.
JAMA internal medicine 2018 Gerrity MS, Prasad V, Obley AJ -
Assessing Pharmaceutical Research and Development Costs-Reply.
JAMA internal medicine 2018 Prasad V, Mailankody S -
Overall Survival vs Disease-Specific Survival-Reply.
JAMA oncology 2018 Mailankody S, Prasad V -
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
BMJ (Clinical research ed.) 2018 Wagner J, Marquart J, Ruby J, Lammers A, Mailankody S, Kaestner V, Prasad V -
Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings.
The Hastings Center report 2018 Hayes MJ, Prasad V -
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
JAMA oncology 2018 Prasad V, Kaestner V, Mailankody S -
Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?
JAMA pediatrics 2018 Prasad V -
The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study.
CMAJ open 2018 Kaestner V, Edmiston JB, Prasad V -
Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?
Journal of general internal medicine 2018 Prasad V -
Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.
JAMA oncology 2018 Gyawali B, Prasad V -
Is "Precision Medicine" Ready to Use in Primary Care Practice? No: It Is Barely Ready for Testing.
American family physician 2017 Prasad V, Obley A -
Clinically meaningful benefit: real world use compared against the American and European guidelines.
Blood cancer journal 2017 Dreicer JJ, Mailankody S, Fakhrejahani F, Prasad V -
Overestimating the Benefit of Cancer Drugs.
JAMA oncology 2017 Prasad V -
Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.
Blood cancer journal 2017 Lammers A, Wang R, Cetnar J, Prasad V -
Me too-drugs with limited benefits - the tale of regorafenib for HCC.
Nature reviews. Clinical oncology 2017 Gyawali B, Prasad V -
Is "Do Everything!" Always Appropriate?-Reply.
JAMA oncology 2017 Beer TM, Prasad V -
Do cancer drugs improve survival or quality of life?
BMJ (Clinical research ed.) 2017 Prasad V -
Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
Nature reviews. Clinical oncology 2017 Prasad V -
Conflicts of interest in Twitter.
The Lancet. Haematology 2017 Kaestner V, Brown A, Tao D, Prasad V -
Evolocumab in Patients with Cardiovascular Disease.
The New England journal of medicine 2017 Redberg RF, Prasad V -
A further strategy to combat the high price of anticancer drugs.
Nature reviews. Clinical oncology 2017 Prasad V, De Jesús K, Mailankody S -
Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.
Nature reviews. Clinical oncology 2017 Gyawali B, Prasad V -
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Seminars in oncology 2017 Prasad V, Kaestner V -
Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings.
Mayo Clinic proceedings 2017 Lammers A, Edmiston J, Kaestner V, Prasad V -
Limitations Concerning the Association of Physician Sex and Patient Outcomes.
JAMA internal medicine 2017 Friedberg MW, Gellad WF, Prasad V -
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
JAMA oncology 2017 Mailankody S, Prasad V -
Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
Cancer 2017 Goldstein DA, Bilal U, Prasad V -
Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement.
JAMA 2017 Mailankody S, Prasad V -
Combining drugs and extending treatment - a PFS end point is not sufficient.
Nature reviews. Clinical oncology 2017 Gyawali B, Prasad V -
Extrarenal Wilms Tumor With Skeletal and Glial Differentiation.
International journal of surgical pathology 2017 Tan GC, Prasad V -
Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote.
The Hastings Center report 2017 De Jesus-Morales K, Prasad V -
Curbing tobacco's reach to improve people's health and futures.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2017 Prasad V, Fu D -
Heparin-induced thrombocytopenia: a tremendous opportunity for randomization.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017 Lammers A, DeLoughery T, Prasad V -
How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted.
The American journal of medicine 2017 Prasad V -
The high price of anticancer drugs: origins, implications, barriers, solutions.
Nature reviews. Clinical oncology 2017 Prasad V, De Jesús K, Mailankody S -
Drugs that lack single-agent activity: are they worth pursuing in combination?
Nature reviews. Clinical oncology 2017 Gyawali B, Prasad V -
Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter.
JAMA internal medicine 2017 Tao DL, Boothby A, McLouth J, Prasad V -
What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature.
Seminars in oncology 2017 Lu E, Shatzel J, Shin F, Prasad V -
The Rising Price of Cancer Drugs-A New Old Problem?
JAMA oncology 2017 Prasad V, Wang R, Afifi SH, Mailankody S -
Pediatric Xanthogranulomatous Cystitis: The First Described Case in a Pre-pubertal Male and Review of the Literature.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2017 Preece J, Prasad V, McLeod D -
A Retrospective Cohort Study of Total Colonic Aganglionosis: Is the Appendix a Reliable Diagnostic Tool?
Journal of neonatal surgery 2017 Reck-Burneo CA, Lane V, Vinay P, Wood R, Levitt M -
Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go.
JAMA oncology 2017 Beer TM, Prasad V -
Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload.
JAMA oncology 2016 Boothby A, Wang R, Cetnar J, Prasad V -
A Strategy for Helicobacter Immunohistochemistry Utilization in Pediatric Practice: Insights From Morphologic and Cost-Benefit Analyses.
American journal of clinical pathology 2016 Conces MR, Arnold CA, Baker PB, Carter CM, Fung B, Prasad V, Arnold MA -
Industry Funding of Cancer Patient Advocacy Organizations.
Mayo Clinic proceedings 2016 Abola MV, Prasad V -
Pediatric Dermatology Photoquiz: An Enlarging Facial Papule.
Pediatric dermatology 2016 Yanes DA, Prasad V, Fernandez Faith E -
Same Data; Different Interpretations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Gyawali B, Prasad V -
Precision medicine in diffuse large B-cell lymphoma: Hype or hope?
European journal of cancer (Oxford, England : 1990) 2016 Prasad V -
Future jobs of FDA's haematology-oncology reviewers.
BMJ (Clinical research ed.) 2016 Bien J, Prasad V -
Perspective: The precision-oncology illusion.
Nature 2016 Prasad V -
Negative trials in ovarian cancer: is there such a thing as too much optimism?
Ecancermedicalscience 2016 Gyawali B, Prasad V -
Precision medicine in acute myeloid leukemia: Hope, hype or both?
Leukemia research 2016 Prasad V, Gale RP -
Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
JAMA 2016 Mailankody S, Prasad V -
Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.
The oncologist 2016 Mailankody S, Prasad V -
Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off?
Journal of general internal medicine 2016 Cifu A, Prasad V -
Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption?
JAMA 2016 Parikh RB, Prasad V -
ASCO Plenary Sessions: impact, legacy, future.
Seminars in oncology 2016 Vandross A, Prasad V, Mailankody S -
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Mayo Clinic proceedings 2016 Prasad V, Mailankody S -
Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?
Medical hypotheses 2016 Prasad V -
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
Mayo Clinic proceedings 2016 Kim C, Prasad V -
Spontaneous Cystic Penile Vascular Malformation in an Adolescent and Review of the Literature.
Urology 2016 Preece J, Prasad V, Schober M, DaJusta DG -
Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply.
JAMA internal medicine 2016 Kim C, Prasad V -
Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration.
JAMA internal medicine 2016 Abola MV, Prasad V -
How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost.
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Prasad V -
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.
The oncologist 2016 Massey PR, Wang R, Prasad V, Bates SE, Fojo T -
Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.
JAMA oncology 2016 Dhruva SS, Prasad V -
Precision oncology: origins, optimism, and potential.
The Lancet. Oncology 2016 Prasad V, Fojo T, Brada M -
Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public.
Oncology (Williston Park, N.Y.) 2016 Prasad VK -
Reply to Dr. Leon: true but unrelated.
Journal of clinical epidemiology 2016 Prasad V -
Why cancer screening has never been shown to "save lives"--and what we can do about it.
BMJ (Clinical research ed.) 2016 Prasad V, Lenzer J, Newman DH -
In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research?
Mayo Clinic proceedings 2016 Prasad V, Berger VW -
The Use of Superlatives in Cancer Research.
JAMA oncology 2016 Abola MV, Prasad V -
Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine.
Journal of global oncology 2015 Prasad V, Kumar H, Mailankody S -
Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?
European journal of heart failure 2015 Vaduganathan M, Prasad V -
Translation failure and medical reversal: Two sides to the same coin.
European journal of cancer (Oxford, England : 1990) 2015 Prasad V -
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
JAMA internal medicine 2015 Kim C, Prasad V -
Medical Debates and Medical Reversal.
Journal of general internal medicine 2015 Cifu AS, Prasad VK -
Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2015 Huded C, Prasad V -
The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?
European journal of cancer (Oxford, England : 1990) 2015 Prasad V, Oseran A, Fakhrejahani F -
Characteristics of Exceptional or Super Responders to Cancer Drugs.
Mayo Clinic proceedings 2015 Prasad V, Vandross A -
Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents.
American family physician 2015 Prasad V -
Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute.
The oncologist 2015 Mailankody S, Prasad V -
Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.
JAMA oncology 2015 Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T -
Pricing and Value of Cancer Drugs--Reply.
JAMA oncology 2015 Mailankody S, Prasad V -
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.
Blood 2015 Prasad V, Mailankody S -
Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov.
European journal of cancer (Oxford, England : 1990) 2015 Prasad V, Goldstein JA -
Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing?
European journal of cancer (Oxford, England : 1990) 2015 Prasad V -
Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start.
Mayo Clinic proceedings 2015 Prasad V, Berger VW -
The role of censoring on progression free survival: oncologist discretion advised.
European journal of cancer (Oxford, England : 1990) 2015 Prasad V, Bilal U -
The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
JAMA internal medicine 2015 Prasad V, Kim C, Burotto M, Vandross A -
Authorship Inflation in Medical Publications.
Inquiry : a journal of medical care organization, provision and financing 2015 Tilak G, Prasad V, Jena AB -
Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy.
Journal of medical genetics 2015 Chung WK, Martin K, Jalas C, Braddock SR, Juusola J, Monaghan KG, Warner B, Franks S, Yudkoff M, Lulis L, Rhodes RH, Prasad V, Torti E, Cho MT, Shinawi M -
Optimization of CO₂ fixation by Chlorella kessleri cultivated in a closed raceway photo-bioreactor.
Bioresource technology 2015 Kasiri S, Ulrich A, Prasad V -
Response.
Chest 2015 Rho J, Ho N, Prasad V -
Distinctive clinical characteristics of malignant mesothelioma in young patients.
Oncotarget 2015 Thomas A, Chen Y, Yu T, Gill A, Prasad V -
Multiplying therapies and reducing toxicity in metastatic melanoma.
Cancer biology & therapy 2015 Massey PR, Prasad V, Figg WD, Fojo T -
Do we need randomised trials for rare cancers?
European journal of cancer (Oxford, England : 1990) 2015 Prasad V, Oseran A -
Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country.
Cancer 2015 Burotto M, Prasad V -
Non-inferiority trials: why oncologists must remain wary.
The Lancet. Oncology 2015 Burotto M, Prasad V, Fojo T -
In situ biodegradation of naphthenic acids in oil sands tailings pond water using indigenous algae-bacteria consortium.
Bioresource technology 2015 Mahdavi H, Prasad V, Liu Y, Ulrich AC -
Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2015 Prasad V, Diener-West M -
Disease specific productivity of american cancer hospitals.
PloS one 2015 Goldstein JA, Prasad V -
But how many people died? Health outcomes in perspective.
Cleveland Clinic journal of medicine 2015 Prasad V -
Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings.
JAMA internal medicine 2015 Jena AB, Prasad V, Goldman DP, Romley J -
Modern drug development: which patients should come first?
JAMA 2014 Vaduganathan M, Prasad V -
The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab.
JAMA internal medicine 2014 Prasad V -
The College of American Pathologists guidelines for whole slide imaging validation are feasible for pediatric pathology: a pediatric pathology practice experience.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2014 Arnold MA, Chenever E, Baker PB, Boué DR, Fung B, Hammond S, Hendrickson BW, Kahwash SB, Pierson CR, Prasad V, Nicol KK, Barr T -
It is time to stop screening for prostate cancer.
JAMA internal medicine 2014 Prasad V -
Primary care physicians' role in counseling about gun safety.
American family physician 2014 Jena AB, Prasad V -
Exemestane with ovarian suppression in premenopausal breast cancer.
The New England journal of medicine 2014 Prasad V -
US News and World Report cancer hospital rankings: do they reflect measures of research productivity?
PloS one 2014 Prasad V, Goldstein JA -
Rosiglitazone, medical reversal, and back to basics for diabetes.
American family physician 2014 Prasad V -
The Peltzman effect and compensatory markers in medicine.
Healthcare (Amsterdam, Netherlands) 2014 Prasad V, Jena AB -
Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality.
Mayo Clinic proceedings 2014 Jena AB, Prasad V, Romley JA -
Statins, primary prevention, and overall mortality.
Annals of internal medicine 2014 Prasad V -
The declining demand for hospital care as a rationale for duty hour reform.
Journal of general internal medicine 2014 Jena AB, DePasse JW, Prasad V -
Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't?
Journal of cancer research and clinical oncology 2014 Prasad V -
Counterpoint: were industry-sponsored roflumilast trials appropriate? No.
Chest 2014 Rho J, Ho N, Prasad V -
Rebuttal from Dr Rho et al.
Chest 2014 Rho J, Ho N, Prasad V -
The reply.
The American journal of medicine 2014 Prasad V, Shea N -
Comparative effectiveness questions in oncology.
The New England journal of medicine 2014 Mailankody S, Prasad V -
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Prasad V, Massey PR, Fojo T -
Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials?
Journal of clinical epidemiology 2014 Prasad V, Ho N -
Can a resident's publication record predict fellowship publications?
PloS one 2014 Prasad V, Rho J, Selvaraj S, Cheung M, Vandross A, Ho N -
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection.
Arteriosclerosis, thrombosis, and vascular biology 2014 Shaked I, Hanna DB, Gleißner C, Marsh B, Plants J, Tracy D, Anastos K, Cohen M, Golub ET, Karim R, Lazar J, Prasad V, Tien PC, Young MA, Landay AL, Kaplan RC, Ley K -
Synovial chondromatosis of the cervical spine: a case report and review of the literature.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2014 Shaw A, Zibly Z, Prasad V, Ikeda D, Boue D, Governale LS -
Shameful.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2014 Prasad V -
Use of the Word "Cure" in the Oncology Literature.
The American journal of hospice & palliative care 2014 Prasad V -
Aditya Jyot-Diabetic Retinopathy in Urban Mumbai Slums Study (AJ-DRUMSS): study design and methodology - report 1.
Ophthalmic epidemiology 2014 Sunita M, Desai S, Vinay P, Moolani S, Rai N, Deepen S, Ashwini R, Manish S, Hemangi G, Abdal O, Kulkarni P, Chakravarti A, Uthra S, Raman R, Radhika S, Natarajan S, Kumaramanickavel G, McCarty C -
Fatal extraintestinal adrenal malignancy in a 12-year-old girl with familial adenomatous polyposis.
Journal of pediatric gastroenterology and nutrition 2014 Rauch LB, Erdman SH, Aldrink JH, Ranalli MA, Prasad V, Hoffman RP -
Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?
Journal of cancer research and clinical oncology 2014 Prasad V, Vandross A -
Does the declining lethality of gunshot injuries mask a rising epidemic of gun violence in the United States?
Journal of general internal medicine 2014 Jena AB, Sun EC, Prasad V -
Media coverage of medical journals: do the best articles make the news?
PloS one 2014 Selvaraj S, Borkar DS, Prasad V -
Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices.
Implementation science : IS 2014 Prasad V, Ioannidis JP -
Comment on "Eliminating chronic kidney disease... as a diagnosis". Authors' reply.
Polskie Archiwum Medycyny Wewnetrznej 2014 Prasad V, Cifu A -
Eliminating chronic kidney disease… as a diagnosis.
Polskie Archiwum Medycyny Wewnetrznej 2014 Prasad V, Cifu A -
Further thoughts on why there are good data supporting the inferior vena cava filter.
JAMA internal medicine 2014 Prasad V, Rho J, Cifu A -
Regarding empiricism and rationalism in medicine and 2 medical worldviews.
Mayo Clinic proceedings 2014 Prasad V -
The accelerated approval of oncologic drugs: lessons from ponatinib.
JAMA 2014 Prasad V, Mailankody S -
The misguided ethics of crossover trials.
Contemporary clinical trials 2013 Prasad V, Grady C -
Dense breasts and legislating medicine.
Cleveland Clinic journal of medicine 2013 Ho N, Kim J, Prasad V -
The reply.
The American journal of medicine 2013 Shea N, Prasad V -
The reversal of cardiology practices: interventions that were tried in vain.
Cardiovascular diagnosis and therapy 2013 Prasad V, Cifu A -
The reply.
The American journal of medicine 2013 Prasad V, Kim J, Rho J -
Firearm legislation and gun-related fatalities.
JAMA internal medicine 2013 Jena AB, Sun EC, Prasad V -
Persistent reservations against the premedical and medical curriculum.
Perspectives on medical education 2013 Prasad V -
Observational studies cannot justify the inferior vena cava filter.
The American journal of medicine 2013 Prasad V -
The inferior vena cava filter--reply.
JAMA internal medicine 2013 Prasad V, Rho J, Cifu A -
Powering cancer screening for overall mortality.
Ecancermedicalscience 2013 Prasad V -
In reply I-reversal of medical practices.
Mayo Clinic proceedings 2013 Prasad V, Cifu A -
The overdiagnosis of pneumonia.
Cleveland Clinic journal of medicine 2013 Prasad V -
Why randomized controlled trials are needed to accept new practices: 2 medical worldviews.
Mayo Clinic proceedings 2013 Prasad V -
Utility of tissue transglutaminase immunohistochemistry in pediatric duodenal biopsies: patterns of expression and role in celiac disease-a clinicopathologic review.
Pathology research international 2013 Almarzooqi S, Houston RH, Prasad V -
Xanthogranulomatous appendicitis in a child: report of a case and review of the literature.
Case reports in medicine 2013 Al-Rawabdeh SM, Prasad V, King DR, Kahwash SB -
Why resident physicians stay late.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2013 Prasad V -
Duty hour reform in a shifting medical landscape.
Journal of general internal medicine 2013 Jena AB, Prasad V -
Osmotic virial coefficients of hydroxyethyl starch from aqueous hydroxyethyl starch-sodium chloride vapor pressure osmometry.
The journal of physical chemistry. B 2013 Cheng J, Gier M, Ross-Rodriguez LU, Prasad V, Elliott JA, Sputtek A -
Handheld ultrasounds: pocket sized, but pocket ready?
The American journal of medicine 2013 Kim JK, Rho J, Prasad V -
Evaluating health system processes with randomized controlled trials.
JAMA internal medicine 2013 Ioannidis JP, Prasad V -
Taking care of sick patients.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2013 Prasad V -
A decade of reversal: an analysis of 146 contradicted medical practices.
Mayo Clinic proceedings 2013 Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, Chacko SJ, Borkar D, Gall V, Selvaraj S, Ho N, Cifu A -
Treatment of moderate to severe hidradenitis suppurativa.
Annals of internal medicine 2013 Prasad V -
Open issues with open access publication.
The American journal of medicine 2013 Shea N, Prasad V -
Routine noninvasive testing and highly sensitive troponin immunoassays--reply.
JAMA internal medicine 2013 Prasad V, Cheung M, Cifu A -
Subclavian vein aneurysm secondary to a benign vessel wall hamartoma.
Pediatric radiology 2013 Warren P, Spaeth M, Prasad V, McConnell P -
Double-crossed: why crossover in clinical trials may be distorting medical science.
Journal of the National Comprehensive Cancer Network : JNCCN 2013 Prasad V -
Falsification end points for observational studies--reply.
JAMA 2013 Jena AB, Prasad V -
The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy?
JAMA internal medicine 2013 Prasad V, Rho J, Cifu A -
Characteristics of cluster randomized trials: are they living up to the randomized trial?
JAMA internal medicine 2013 Selvaraj S, Prasad V -
Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes.
Journal of clinical epidemiology 2013 Prasad V, Jorgenson J, Ioannidis JP, Cifu A -
Prespecified falsification end points: can they validate true observational associations?
JAMA 2013 Prasad V, Jena AB -
Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more.
Annals of gastroenterology 2013 Ho N, Prasad V -
When research evidence is misleading.
The virtual mentor : VM 2013 Huded C, Rosno J, Prasad V -
Couple therapy for posttraumatic stress disorder.
JAMA 2012 Prasad V -
Holiday reading: The facts are the facts.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2012 Prasad V -
Freedom to innovate: the perils of centralized medical research-reply.
Archives of internal medicine 2012 Prasad V, Rho J, Cifu A -
An unmeasured harm of screening.
Archives of internal medicine 2012 Prasad V -
Chest pain in the emergency department: the case against our current practice of routine noninvasive testing.
Archives of internal medicine 2012 Prasad V, Cheung M, Cifu A -
Raise the bar even higher for primary prevention interventions-reply.
Archives of internal medicine 2012 Prasad V, Vandross A -
Publication trends among internal medicine residents and graduates.
The American journal of medicine 2012 Prasad V, Rho J, Selvaraj S, Toomey C, Vandross A, Ho N -
The conundrum of cost-effectiveness.
Cleveland Clinic journal of medicine 2012 Prasad V -
The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era.
Archives of internal medicine 2012 Prasad V, Rho J, Cifu A -
The apples and oranges of cost-effectiveness.
Cleveland Clinic journal of medicine 2012 Prasad V -
Cardiovascular primary prevention: how high should we set the bar?
Archives of internal medicine 2012 Prasad V, Vandross A -
New frontiers for stroke prevention in atrial fibrillation.
Cerebrovascular diseases (Basel, Switzerland) 2012 Prasad V, Kaplan RM, Passman RS -
Reversals of established medical practices: evidence to abandon ship.
JAMA 2012 Prasad V, Cifu A, Ioannidis JP -
Medical reversal: why we must raise the bar before adopting new technologies.
The Yale journal of biology and medicine 2011 Prasad V, Cifu A -
Selective therapeutic hypothermia: a review of invasive and noninvasive techniques.
Arquivos de neuro-psiquiatria 2011 Straus D, Prasad V, Munoz L -
The cardiovascular biomarker conundrum: challenges and solutions.
JAMA 2011 Prasad V, Bonow RO -
Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes.
Teaching and learning in medicine 2011 Prasad V -
Clostridium difficile diarrhea and fecal transplantation.
Journal of clinical gastroenterology 2011 Ho N, Prasad V -
The frequency of medical reversal.
Archives of internal medicine 2011 Prasad V, Gall V, Cifu A -
Effect of clinical vignettes on senior medical students' opinions of climate change.
Southern medical journal 2011 Prasad V, Thistlethwaite W, Dale W -
Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation.
Journal of clinical gastroenterology 2011 Ho N, Prasad V -
Steroids in infection: an old wives' tale.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2011 Prasad V -
Caution needed when predicting problem residents.
Academic medicine : journal of the Association of American Medical Colleges 2011 Prasad V -
Holiday reading: A la carte medicine.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2010 Prasad V -
Baseline event rate, the Concorde fallacy, and the topography of cardiac risk.
Medical hypotheses 2010 Prasad V -
Language in the end. Explaining the death of a loved one.
Journal of general internal medicine 2010 Prasad V -
Reclaiming the morbidity and mortality conference: between Codman and Kundera.
Medical humanities 2010 Prasad V -
Perspective: beyond storytelling in medicine: an encounter-based curriculum.
Academic medicine : journal of the Association of American Medical Colleges 2010 Prasad V -
Toward a meaningful alternative medicine.
The Hastings Center report 2009 Prasad V